Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.44 USD
Change Today +0.10 / 4.27%
Volume 323.4K
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

durect corporation (DRRX) Snapshot

Open
$2.34
Previous Close
$2.34
Day High
$2.44
Day Low
$2.30
52 Week High
04/24/15 - $2.65
52 Week Low
10/27/14 - $0.68
Market Cap
291.7M
Average Volume 10 Days
613.8K
EPS TTM
$-0.20
Shares Outstanding
119.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DURECT CORPORATION (DRRX)

durect corporation (DRRX) Related Businessweek News

No Related Businessweek News Found

durect corporation (DRRX) Details

DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. It provides ALZET product line comprising osmotic pumps and accessories that are used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers, which are used as raw materials for pharmaceutical and medical device under the LACTEL brand. It also focuses on developing products for various chronic and episodic, or acute medical conditions, including pain, central nervous system disorders, metabolic disorders, cardiovascular disease, ophthalmic disorders, and other diseases. The company develops REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a transdermal bupivacaine for the treatment of pain associated with post-herpetic neuralgia; and Relday, a risperidone product to treat the symptoms of schizophrenia and bipolar I disorder in adults and teenagers. It also develops ORADUR-ADHD, a drug candidate for the treatment of attention deficit hyperactivity disorder; ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials to treat chronic pain, and oxymorphone; and DUR-928, an endogenous small molecule for the treatment of acute organ injuries and metabolic/lipid disorders. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd., Impax Laboratories, Inc., Zogenix, Inc., Pain Therapeutics, Inc., and Hospira, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

103 Employees
Last Reported Date: 05/1/15
Founded in 1998

durect corporation (DRRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $470.4K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $277.5K
Chief Financial Officer
Total Annual Compensation: $322.1K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $275.8K
Executive Vice President of Pharmaceutical Sy...
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2014.

durect corporation (DRRX) Key Developments

DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study

DURECT Corporation announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury.

DURECT Corporation Announces Information About Clinical Trials and its Plans for REMOXY

On May 11 and 12, 2015, DURECT Corporation's licensee for REMOXY, Pain Therapeutics Inc. (Pain Therapeutics), announced information about clinical trials and its plans for REMOXY, a novel long-acting oral formulation of the opioid oxycodone targeted to decrease the potential for oxycodone abuse. DURECT licensed development and commercialization rights to REMOXY to Pain Therapeutics, and Pain Therapeutics subsequently licensed these rights to King Pharmaceuticals Inc. (King). King was later acquired by Pfizer Inc. (Pfizer), and in October 2014, Pfizer informed Pain Therapeutics that it was returning its development and commercialization rights for REMOXY to Pain Therapeutics. Under the terms of DURECT's agreement with Pain Therapeutics, if REMOXY is commercialized, DURECT will receive royalties of between 6.0% to 11.5% of net sales depending on sales volumes.

Durect Corporation Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Durect Corporation announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $4,773,000 against $6,293,000 a year ago. Income from operations was $4,420,000 against $3,602,000 a year ago. Net loss was $4,853,000 or $0.04 basic and diluted per share against $3,600,000 or $0.03 basic and diluted per share a year ago, due to R&D expense, SG&A expenses plus interest expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRX:US $2.44 USD +0.10

DRRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Egalet Corp $9.07 USD -0.07
Elite Pharmaceuticals Inc $0.20 USD -0.0041
Supernus Pharmaceuticals Inc $13.44 USD +0.18
Veloxis Pharmaceuticals A/S kr1.02 DKK +0.02
Zogenix Inc $1.40 USD 0.00
View Industry Companies
 

Industry Analysis

DRRX

Industry Average

Valuation DRRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.5x
Price/Book 18.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DURECT CORPORATION, please visit www.durect.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.